Study identifier:NIS-CCZ-CRE-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Statin Therapy Results in the Real World Practice in the Czech Republic
dyslipidaemia
-
No
-
All
3253
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Statins are the first choice treatment of dyslipidemia, a major contributor to cardiovascular diseases. Statins also have enough evidence to demonstrate decrease of morbidity and mortality from cardiovascular diseases. Even though statin therapy is effective treatment of dyslipidaemia not all patients reach the goal levels. The aim of the study is to estimate proportion of patients who achieved the therapeutic goal (LDL-C. total cholesterol, HDL-C and triglycerides levels) after at least one year of a statin therapy.
Location
Location
Benesov, Czech Republic
Location
Beroun, Czech Republic
Location
Blansko, Czech Republic
Location
Bohumin, Czech Republic
Location
Boskovice, Czech Republic
Location
Brandys nad Labem, Czech Republic
Location
Brno, Czech Republic
Location
Ceska Lipa, Czech Republic
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.